Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled

Inclusion Criteria: 1. More than 20 years in hypertension patient 2. Hypertension is satisfied with the Clinic blood pressure that was measured at the time of screening * Treatment-Naive: Clinic Mean sitting diastolic blood pressure ≥ 100mmHg. * Treatment-Experienced: Clinic Mean sitting diastolic blood pressure ≥ 90mmHg. 3. Hypertension is satisfied with the Clinic blood pressure that was measured at the time of randomization * Clinic Mean sitting diastolic blood pressure ≥ 90mmHg 4. Patient who decided to participate and signed on an informed consent form willingly Exclusion Criteria: 1. Clinic Mean sitting systolic blood pressure ≥ 180mmHg or Clinic Mean sitting diastolic blood pressure ≥ 115mmHg at the time of Screening and Randomization 2. As night workers who sleep during the day and whose working hours including 00:00 to 04:00 3. Secondary Hypertension 4. Severe heart disease(Heart failure; New York Heart Association(NYHA) class 3, 4) and recent unstable angina or myocardial infarction or valvular heart disease or arrhythmia requiring treatment within the past 3 months 5. Severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage within 6 months 6. type 1 diabetes mellitus or Uncontrolled type 2 diabetes mellitus(HbA1c \> 8.0%) 7. Severe or malignant retinopathy 8. Abnormal laboratory test results * Aspartate aminotransferase/Alanine aminotransferase \> Upper normal limit X 2 * Serum creatinine \> Upper normal limit X 2 9. Acute of chronic inflammatory status requiring treatment 10. Need for other antihypertensive drugs during the trial 11. Need for prohibited medication specified in the protocol 12. A history of angioedema with ACE inhibitors or angiotensin-Ⅱ receptor blockers 13. Severe hypersensitivity to amlodipine or telmisartan 14. History of drug or alcohol abuse within 6 months 15. Surgical or medical conditions * History of major gastrointestinal surgery * History of active inflammatory bowel syndrome within 12 months * Abnormal pancreatic functions * Gastrointestinal/rectal bleeding * Urinary tract obstruction 16. Administration of other Investigational Product within 30 days 17. Pregnant, breast-feeding and childbearing age who don't use adequate contraception 18. History of malignant tumor within 5 years (including leukemia and lymphoma) 19. Another clinical condition in investigator's judgement